References: 

• 1. M. Guzman and E. Harris, Dengue, Lancet., 385 (2015), 453–465.
• 2. A. Wilder-Smith, Risk of Dengue in Travelers: Implications for Dengue Vaccination, Curr. Infect. Dis. Rep., 20 (2018), 50.
• 3. S. Masyeni, B. Yohan, I. Somia, K. S. A. Myint, and R. T. Sasmono, Dengue infection in international travellers visiting Bali, Indonesia, J. Travel. Med., 25 (2018), 1–7.
• 4. A. Riddell and Z. O. E. Babiker, Imported dengue fever in East London: A 6-year retrospective observational study, J. Travel. Med., 24 (2017), 1–6.
• 5. S. Rabinowicz and E. Schwartz, Morbidity among Israeli paediatric travelers, J. Travel. Med., 24 (2017), 1–7.
• 6. A. Wilder-Smith, Serostatus-dependent performance of the first licensed dengue vaccine: Implications for travelers, J. Travel. Med., 25 (2018), 1–3.
• 7. O. J. Brady, P. W. Gething, S. Bhatt, J. P. Messina, J. S. Brownstein, A. G. Hoen, C. L. Moyes, A. W. Farlow, T. W. Scott and S. I. Hay, Refining the global spatial limits of dengue virus transmission by evidence-based consensus, PLoS. Negl. Trop. Dis., 6 (2012), e1760.
• 8. S. Bhatt, P. W. Gething, O. J. Brady, J. P. Messina, A. W. Farlow, C. L. Moyes, J. M. Drake, J. S. Brownstein, A. G. Hoen, O. Sankoh, M. F. Myers, D. B. George, T. Jaenisch, G. R. Wint, C. P. Simmons, T. W. Scott, J. J. Farrar and S. I. Hay, The global distribution and burden of dengue, Nature., 496 (2013), 504–507.
• 9. E. S. Jentes, R. R. Lash, M. A. Johansson, T. M. Sharp, R. Henry, O. J. Brady, M. J. Sotir, S. I. Hay, H. S. Margolis and G. W. Brunette, Evidence-based risk assessment and communication: A new global dengue-risk map for travellers and clinicians, J. Travel. Med., 23 (2016), 1–5.
• 10. S. Halstead, Dengue, Lancet., 370 (2007), 1644–1652.
• 11. S. M. Lok, The interplay of dengue virus morphological diversity and human antibodies, Trends. Microbiol., 24 (2016), 284–293.
• 12. D. M. Morens, Antibody-dependent enhancement of infection and the pathogenesis of viral disease, Clin. Infect. Dis., 19 (1994), 500–512.
• 13. T. C. Pierson and M. S. Diamond, Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection, Expert. Rev. Mol. Med., 10 (2008), e12.
• 14. J. R. Stephenson, Understanding dengue pathogenesis: Implications for vaccine design, B. World. Health. Organ., 83 (2005), 308–314.
• 15. M. Aguiar, N. Stollenwerk and S. B. Halstead, The impact of the newly licensed dengue vaccine in endemic countries, PLoS. Negl. Trop. Dis., 10 (2016), e0005179.
• 16. The Lancet Infectious Diseases, The dengue vaccine dilemma, Lancet. Infect. Dis., 18 (2018): 123.
• 17. K. K. Ariën and A. Wilder-Smith, Dengue vaccine: Reliably determining previous exposure, Lancet. Glob. Health., 6 (2018), e830–e831.
• 18. Sanofi, Sanofi updates information on dengue vaccine, Available from: https://mediaroom.sanofi.com/en/press-releases/2017/sanofi-updates-information-on-dengue-vaccine/.
• 19. WHO, Updated Questions and Answers related to information presented in the Sanofi Pasteur press release on 30 November 2017 with regards to the dengue vaccine Dengvaxia, Available from: https://www.who.int/immunization/diseases/dengue/q_and_a_dengue_vaccine_dengvaxia/en/.
• 20. A. Wilder-Smith, K. S. Vannice, J. Hombach, J. Farrar and T. Nolan, Population perspectives and World Health Organization recommendations for CYD-TDV dengue vaccine, J. Infect. Dis., 214 (2016), 1796–1799.
• 21. The SAGE Working Group on Dengue Vaccines and WHO Secretariat, Background paper on dengue vaccines 2018, Available from: https://www.who.int/immunization/sage/meetings/2018/april/2_DengueBackgrPaper_SAGE_Apr2018.pdf?ua=1.
• 22. Dengue vaccine: WHO position paper, Wkly. Epidemiol. Rec., 36 (2018), 457–476.
• 23. A. Wilder-Smith, J. Hombach, N. Ferguson, M. Selgelid, K. O'Brien, K. Vannice, A. Barrett, E. Ferdinand, S. Flasche, M. Guzman, H. M. Novaes, L. C. Ng, P. G. Smith, P. Tharmaphornpilas, I. K. Yoon, A. Cravioto, J. Farrar and T. M. Nolan, Deliberations of the strategic advisory group of experts on immunization on the use of CYD-TDV dengue vaccine, Lancet. Infect. Dis., 19 (2018), e31–e38.
• 24. H. S. Rodrigues, M. T. T. Monteiro and D. F. M. Torres, Vaccination models and optimal control strategies to dengue, Math. Biosci., 247 (2014), 1–12.
• 25. S. B. Maier, X. Huang, E. Massad, M. Amaku, M. N. Burattini and D. Greenhalgh, Analysis of the optimal vaccination age for dengue in Brazil with a tetravalent dengue vaccine, Math. Biosci., 294 (2017), 15–32.
• 26. N. M. Ferguson, I. Rodríguez-Barraquer, I. Dorigatti, L. Mier-Y-Teran-Romero, D. J. Laydon and D. A. Cummings, Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment, Science., 353 (2016), 1033–1036.
• 27. F. B. Agusto and M. A. Khan, Optimal control strategies for dengue transmission in Pakistan, Math. Biosci., 305 (2018), 102–121.
• 28. T. T. Zheng and L. F. Nie, Modelling the transmission dynamics of two-strain Dengue in the presence awareness and vector control, J. Theor. Biol., 443 (2018), 82–91.
• 29. C. Guo, Z. Zhou, Z. Wen, Y. Liu, C. Zeng, D. Xiao, M. Ou, Y. Han, S. Huang, D. Liu, X. Ye, X. Zou, J. Wu, H. Wang, E. Y. Zeng, C. Jing and G. Yang, Global Epidemiology of Dengue Outbreaks in 1990–2015: A Systematic Review and Meta-Analysis, Front. Cell. Infect. Microbiol., 7 (2017), 317.
• 30. S. B. Halstead and P. K. Russell, Protective and immunological behavior of chimeric yellow fever dengue vaccine, Vaccine., 34 (2016), 1643–1647.
• 31. E. A, Undurraga, M. Betancourt-Cravioto, J. Ramos-Castaneda, R. Martínez-Vega, J. Méndez-Galván, D. J. Gubler, M. G. Guzmán, S. B. Halstead, E. Harris, P. Kuri-Morales, R. Tapia-Conyer and D. S. Shepard, Economic and disease burden of dengue in Mexico, PLoS. Negl. Trop. Dis., 9 (2015), e0003547.
• 32. D. S. Shepard, E. A. Undurraga, Y. A. Halasa and Stanaway JD, The global economic burden of dengue: A systematic analysis, Lancet. Infect. Dis., 16 (2016), 935–941.
• 33. N. Pavia-Ruz, D. P. Rojas, S. Villanueva, P. Granja, A. Balam-May, I. M. Longini, M. E. Halloran, P. Manrique-Saide and H. Gómez-Dantés, Seroprevalence of Dengue Antibodies in Three Urban Settings in Yucatan, Mexico, Am. J. Trop. Med. Hyg., 98 (2018), 1202–1208.
• 34. M. L. Cafferata, A. Bardach, L. Rey-Ares, A. Alcaraz, G. Cormick, L. Gibbons, M. Romano, S. Cesaroni and S. Ruvinsky, Dengue epidemiology and burden of disease in Latin America and the Caribbean: A systematic review of the literature and meta-analysis, Value. Health. Region. Issues., 2 (2013), 347–356.
• 35. D. S. Shepard, L. Coudeville, Y. A. Halasa, B. Zambrano and G. H. Dayan, Economic impact of dengue illness in the Americas, Am. J. Trop. Med. Hyg., 84 (2011), 200–207.
• 36. E. Shim, Cost-effectiveness of dengue vaccination in Yucatan, Mexico using a dynamic dengue transmission model, PLoS. One., 12 (2017), e0175020.
• 37. E. Shim, Optimal strategies of social distancing and vaccination against seasonal influenza, Math. Biosci. Eng., 10 (2013), 1615–1634.
• 38. D. Aldila, T. Götz and E. Soewono, An optimal control problem arising from a dengue disease transmission model, Math. Biosci., 242 (2013), 9–16.
• 39. S. Lee and C. Castillo-Chavez, The role of residence times in two-patch dengue transmission dynamics and optimal strategies, J. Theor. Biol., 374 (2015), 152–164.
• 40. W. Fleming and R. Rishel, Deterministic and Stochastic Optimal Control, Springer Verlag, (1975).
• 41. S. Lenhart and J. Workman, Optimal Control Applied to Biological Models, Chapman and Hall/CRC, (2007).
• 42. R. J. Cox, K. A. Brokstad and P. L. Ogra, Influenza virus: Immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines, Scand. J. Immunol., 59 (2004), 1–15.
• 43. E. Hansen and T. Day, Optimal control of epidemics with limited resources, J. Math. Biol., 62 (2011), 423–451.
• 44. E. A. Bakare, A. Nwagwo and E. Danso-Addo, Optimal control analysis of an SIR epidemic model with constant recruitment, Int. J. Appl. Math. Res., 3 (2014), 273–285.
• 45. L. S. Pontryagin, V. G. Boltyanskii and R. V. Gamkrelidze and E. F. Mishchenko, Mathematical Theory of Optimal Processes, Wiley, (1962).
• 46. R. L. M. Neilan, E. Schaefer and H. Gaff and K. R. Fister and S. Lenhart, Modeling optimal intervention strategies for cholera, Bull. Math. Biol., 72 (2010), 2004–2018.
• 47. P. van den Driessche and J. Watmough, Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission, Math. Biosci., 180 (2002), 29–48.
• 48. S. T. R. Pinho, C. P. Ferreira and L. Esteva, F. R. Barreto, V. C. Morato e Silva and M. G. Teixeira, Modelling the dynamics of dengue real epidemics, Philos. Trans. Math. Phys. Eng. Sci., 368 (2010), 5679–5693.
• 49. R. P. Sanches and E. Massad, A comparative analysis of three different methods for the estimation of the basic reproduction number of dengue, Infect. Dis. Model., 1 (2016), 88–100.
• 50. I. Dorigatti, R. Aguas, C. A. Donnelly, B. Guy, L. Coudeville, N. Jackson, M. Saville and N. M. Ferguson, Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia, Vaccine., 33 (2015), 3746–3751.
• 51. I. Y. Amaya-Larios, R. A. Martinez-Vega, S. V. Mayer, M. Galeana-Hernández, A. Comas-García, K. J. Sepúlveda-Salinas, J. A. Falcón-Lezama, N. Vasilakis, and J. Ramos-Castañeda, Seroprevalence of neutralizing antibodies against dengue virus in two localities in the state of Morelos, Mexico, Am. J. Trop. Med. Hyg., 91 (2014), 1057–1065.
• 52. S. Sridhar, A. Luedtke, E. Langevin, M. Zhu, M. Bonaparte, T. Machabert, S. Savarino, B. Zambrano, A. Moureau, A. Khromava, Z. Moodie, T. Westling, C. Mascareñas, C. Frago, M. Cortés, D. Chansinghakul, F. Noriega, A. Bouckenooghe, J. Chen, S. P. Ng, P. B. Gilbert, S. Gurunathan and C. A. DiazGranados, Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy, N. Engl. J. Med., 379 (2018), 327–340.
• 53. N. Imai and N. Ferguson, Targeting vaccinations for the licensed dengue vaccine: Considerations for serosurvey design, PLoS. One., 13 (2018), e0199450.
• 54. M. Aguiar, Dengue vaccination: A more ethical approach is needed, Lancet., 391 (2018), 1769–1770.
• 55. S. Hadinegoro, J. Arredondo-Garcia, M. Capeding, C. Deseda, T. Chotpitayasunondh, R. Dietze, H. I. Muhammad Ismail, H. Reynales, K. Limkittikul, D. M. Rivera-Medina, H. N. Tran, A. Bouckenooghe, D. Chansinghakul, M. Cortés, K. Fanouillere, R. Forrat, C. Frago, S. Gailhardou, N. Jackson, F. Noriega, E. Plennevaux, T. A. Wartel, B. Zambrano, and M. Saville, Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease, N. Engl. J. Med., 373 (2015), 1195–1206.
• 56. B. Gessner and A. Wilder-Smith, Estimating the public health importance of the CYD-tetravalent dengue vaccine: Vaccine preventable disease incidence and numbers needed to vaccinate, Vaccine., 34 (2016), 2397–2401.
• 57. L. Coudeville, N. Baurin, M. L'Azou and B. Guy, Potential impact of dengue vaccination: Insights from two large-scale phase III trials with a tetravalent dengue vaccine, Vaccine., 34 (2016), 6426–6435.
• 58. B. Adams and M. Boots, Modelling the relationship between antibody-dependent enhancement and immunological distance with application to dengue, J. Theor. Biol., 242 (2006), 337–346.
• 59. M. Ndeffo Mbah, D. Durham, J. Medlock and A. P. Galvani, Country- and age-specific optimal allocation of dengue vaccines, J. Theor. Biol., 342 (2014), 15–22.
• 60. M. Johansson, J. Hombach and D. Cummings, Models of the impact of dengue vaccines: A review of current research and potential approaches, Vaccine., 29 (2011), 5860–5868.
• 61. N. Honorio, R. Nogueira, C. Codeco, M. S. Carvalho, O. G. Cruz, A. Magalhães Mde, J. M. de Araújo, E. S. de Araújo, M. Q. Gomes, L. S. Pinheiro, C. da Silva Pinel and R. Lourenço-de-Oliveira, Spatial evaluation and modeling of Dengue seroprevalence and vector density in Rio de Janeiro, Brazil, PLoS. Negl. Trop. Dis., 3 (2009), e545.

show all references